- Home
- SENEB vs CRMD Comparison
SENEB vs CRMD Comparison
Compare SENEB & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SENEB | CRMD |
|---|---|---|
| Founded | 1949 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 813.0M | 958.1M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | SENEB | CRMD |
|---|---|---|
| Price | $110.27 | $7.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $17.29 |
| AVG Volume (30 Days) | 447.0 | ★ 3.7M |
| Earning Date | 02-05-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 47.79 | N/A |
| EPS | ★ 8.61 | 2.25 |
| Revenue | ★ $1,606,175,000.00 | $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | N/A | $40.95 |
| P/E Ratio | $12.84 | ★ $3.33 |
| Revenue Growth | 8.33 | ★ 1647.67 |
| 52 Week Low | $71.47 | $5.60 |
| 52 Week High | $124.94 | $17.43 |
Technical Indicators
Market Signals| Indicator | SENEB | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.40 | 26.25 |
| Support Level | $109.56 | $7.22 |
| Resistance Level | $115.00 | $12.29 |
| Average True Range (ATR) | 0.39 | 0.70 |
| MACD | -1.65 | -0.52 |
| Stochastic Oscillator | 9.78 | 8.02 |
Price Performance
Historical ComparisonAbout SENEB Seneca Foods Corp. Class B
Seneca Foods Corp is a US-based company which acts as a provider of packaged fruits and vegetables. Its product offerings include canned, frozen, and bottled produce and snack chips. The company's segment includes Vegetable and Fruit/Snack. It generates maximum revenue from the Vegetable segment.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.